Pipeline

A powerful approach

We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options.

Development Pipeline

Program
Patient Selection
Indications
Clinical Trials
Status
PRMT5 TNG462
MTAPdel cancers
Pancreatic, lung, other non-CNS cancer
Pre-clinical
Phase 1/2
Phase 3
Dose expansion ongoing
Phase 1/2
PRMT5 TNG462
MTAPdel/RASmut (RevMed)
Pancreatic and lung cancer
Dose escalation ongoing
Phase 1/2
PRMT5 TNG456
MTAPdel cancers
Glioblastoma
Dose escalation ongoing
Phase 1/2
HBS1L TNG961
MTAP/FOCADdel cancers
Solid tumors
IND-enabling studies
Pre-clinical
CoREST TNG260
STK11mut/RAS WT cancers
Lung cancer
Dose expansion ongoing
Phase 1/2

All programs wholly owned by Tango

Partnerships

We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: bd@tangotx.com.

Learn more about the culture of innovation at Tango.Learn more about the culture of innovation at Tango.